More than six months have passed since the full implementation of the Hong Kong Competition Ordinance on 14 December 2015. We highlight the most significant developments over the past six months.
China’s National Development and Reform Commission published Draft Guidelines on the Determination of Illegal Gains and Fines in Relation to Business Operators’ Monopolistic Conduct for public consultation.
China’s National Development and Reform Commission formally launched a large scale and systematic antitrust and price inspection into China’s pharmaceutical and medical devices industries
Recently published antitrust decisions by China’s two leading antitrust enforcers show that the pharma sector remains an antitrust enforcement target in China.
On 19 November 2015, the Hong Kong Competition Commission published its long-awaited Enforcement Policy. The same day, the Commission released its Leniency Policy for Undertakings Engaged in Cartel Conduct.
On 15 October 2015, Mofcom and the European Commission entered into a best practices framework for cooperation in reviewing mergers. The framework marks growing cooperation between regulators handling multinational transactions. Find out what this means in practice.
On 7 April 2015, the State Administration for Industry and Commerce (“SAIC”) published the long awaited Regulation on the Prohibition of Conduct Eliminating or Restricting Competition by Abusing Intellectual Property Rights (the “Rules”), which will come into effect on 1 August 2015. The Rules are the first set of regulations…
On 30 March 2015, the Hong Kong Competition Commission released its revised draft guidelines, following a public consultation process that was conducted from mid to late 2014. This brings the Commission and the Government one step closer to implementation of the Competition Ordinance (expected to come into force later this…
In November 2014, widespread press reports in China announced that Chinese competition authorities would imminently commence investigations into foreign manufacturers of medical devices for suspected anti-competitive behavior, in particular in connection with after-sales services. The reports suggested that the investigations would reflect complaints over the high maintenance costs of foreign…